Atlas Trials

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

Clinical trial NCT03528408 · UNKNOWN

Trial details

NCT number
NCT03528408
Sponsor
Suthee Rapisuwon
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
MelanomaOcular Melanoma
Start date
2018-07-26
Primary completion
2023-05-01
Enrollment
52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.